Skip to content
Traxsy
All articles

Medication

Ozempic®, Mounjaro® and Zepbound®: what each US label covers

General information, not medical advice. Talk to your prescriber or pharmacist about your own treatment.

In the US, Ozempic® and Mounjaro® are approved to treat type 2 diabetes, and Zepbound® for weight management and sleep apnea in certain adults. A note on reading the labels, not on which works better.

Full article coming soon

This page is a short summary. The full article is still being written and checked against its sources.

Sources

  1. Ozempic® (semaglutide) US prescribing information — DailyMed
  2. Mounjaro® (tirzepatide) US prescribing information, section 12.3 — DailyMed
  3. Zepbound® (tirzepatide) US prescribing information — DailyMed

Sources checked October 1, 2026

  • Ozempic label
  • Mounjaro label
  • Zepbound label
  • GLP-1 indications
Traxsy

A GLP-1 medication tracker for iPhone. Log doses, weight and side effects, and see how they line up.

Coming soon to the App Store · iPhone

© 2026 Traxsy

Traxsy is a tracking tool and does not provide medical advice, diagnosis or treatment. Always follow your prescriber.

Ozempic®, Wegovy®, Rybelsus®, Victoza® and Saxenda® are trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound® and Trulicity® are trademarks of Eli Lilly and Company. Traxsy is not affiliated with or endorsed by them.